Zydus receives final approval from the USFDA for Amitriptyline Hydrochloride Tablets USP

Ahmedabad, 07 October 2017

Zydus Cadila has received the final approval from the USFDA to market Amitriptyline Hydrochloride Tablets USP in strengths of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg. The drug is used to treat depression and will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
